

REMARKS/ARGUMENTS

Status of the Claims

Claims 1, 3, 4 and 9 are pending in the present application. Claims 2, 5-8, and 10 have been canceled without prejudice. Applicants reserve the right to claim any disclaimed subject matter in a co-pending, related application. Claims 1, 3, 4, and 9 have been amended. The amendments are supported in the originally filed specification. As such, no new matter has been added. Reconsideration is respectfully requested.

Claim Rejections - 35 USC § 112, first paragraph, written description

The Examiner has rejected claims 1-6 and 9-10 under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the written description requirement. The Examiner asserts that Applicants have not demonstrated that any GWT1 gene, other than the *Saccharomyces cerevisiae* gene (SEQ ID NO: 1), can be used to identify test samples that decrease GlcN-(acyl)PI.

Without acquiescing to the Examiner's position, claim 1 has been amended to further expedite prosecution. As described above, amended claim 1 is directed in-part to a method of screening for a sample that decreases GlcN-(acyl)PI, wherein the method comprises the steps of "(1) contacting a test sample with an overexpressed protein encoded by the GWT1 gene of the following (a) or (b); (a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO:2; (b) a DNA comprising the nucleotide sequence of SEQ ID NO: 1." As amended, Applicants submit that the current scope should satisfy the Examiner in view of the comments made in the Office Action.

Claims 3, 4 and 9 should be allowable for at least depending from now allowable claim 1. Claims 2, 5 and 6 are canceled without prejudice or disclaimer; thus, the rejection of these claims is moot.

Accordingly, Applicants request that the Examiner withdraw the rejection to claims 1-6 and 9-10 under 35 U.S.C. § 112, first paragraph as to written description.

Rejections under 35 U.S.C. § 112, first paragraph, enablement

The Examiner has rejected claims 1-6 and 9-10 under 35 U.S.C. § 112, first paragraph, as allegedly failing to meet the enablement requirement. In particular, the Examiner alleges that the specification is only enabling for a method of detecting the function of a GWT1 gene, wherein the method comprises the steps of: (1) contacting a test sample with an overexpressed protein (SEQ ID NO:2) encoded by the GWT1 gene (SEQ ID NO: 1); (2) detecting GlcN-(acyl)PI; and (3) selecting the test sample that decreases GlcN-(acyl)PI.

Without acquiescing to the Examiner's position, claim 1 has been amended to further expedite prosecution. As described above, amended claim 1 is directed in-part to a step of“(1) contacting a test sample with an overexpressed protein encoded by the GWT1 gene of the following (a) or (b); (a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO:2; (b) a DNA comprising the nucleotide sequence of SEQ ID NO: 1.” As amended, Applicants submit that the current scope should satisfy the Examiner in view of the comments made in the Office Action.

Claims 3, 4 and 9 should be allowable for at least depending from now allowable claim 1. Claims 2, 5 and 6 are canceled without prejudice or disclaimer; thus, the rejection of these claims is moot.

Accordingly, Applicants request that the Examiner withdraw the rejection to claims 1-6 and 9-10 under 35 U.S.C. § 112, first paragraph as to enablement.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested. If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at 415-576-0200.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachments
KLB:dlh
62845451 v1